PT-141 · bremelanotide · pharmacokinetics · research use only
PT-141 half-life: a short, acute clock.
PT-141 (bremelanotide) does not behave like the daily- or weekly-cadence peptides researchers more often source. Its reported elimination half-life is short — about 2.7 hours, with a literature range of roughly 1.9 to 4.0 hours — which places it firmly in the acute, single-window end of the kinetic spectrum. This page explains what that half-life means for how the compound is studied, why the intranasal format changes the curve versus an injection, and why it is a laboratory reference, not a human protocol or medical advice.
~2.7 hours, not days
Bremelanotide's elimination half-life is reported at approximately 2.7 hours (range ~1.9-4.0 hours). That is short relative to GH-secretagogue or repair peptides studied on multi-day cadences. The practical consequence is that PT-141 is modelled as an acute, single-window compound — its concentration rises and falls within a single session rather than accumulating across days.
How that shapes the window →A melanocortin-agonist clock
PT-141 is studied as a melanocortin-receptor agonist — a cyclic heptapeptide that acts on a different pathway than the GHRH/GHRP or GLP-1 compounds elsewhere in the catalog. Its kinetics are read on the melanocortin clock: short systemic exposure, with downstream signalling timing that the literature treats separately from plasma clearance.
PT-141 vs Melanotan II →Nasal vs injection changes the curve
Titan supplies PT-141 as a metered nasal spray. Route matters to kinetics: the published ~2.7-hour figure is anchored to subcutaneous administration with full bioavailability, while intranasal delivery has its own absorption profile and typically lower, faster-peaking exposure. The half-life describes elimination once absorbed; the route shapes how quickly and how much is absorbed in the first place.
Two nasal sprays compared →Acute window, not accumulation
Because the half-life is short and exposure does not stack across days, PT-141 research protocols model it around a single window rather than a steady-state level. That is the opposite design from a long-half-life peptide — the question is the size and timing of one window, not how a daily dose accumulates. See the dosage reference for the modelled ranges.
Modelled ranges →Lot purity changes the curve
Half-life figures assume the material matches its label. A degraded or mislabelled lot shifts the effective amount and undermines any kinetic modelling. Titan's PT-141 nasal spray ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet, so the starting material is characterised before any modelling.
See the testing workflow →Research-use framing
PT-141 / bremelanotide is supplied strictly as a research-use-only reagent. The half-life figures here are reproduced as a laboratory reference for in-vitro and modelling work — not instructions for human use, and not a statement about any physiological effect. Nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
The acute window, in plain figures.
PT-141's kinetics read differently from the chronic-cadence peptides — short half-life, single-window modelling, route-dependent absorption. These are the figures a research protocol weighs, reproduced as a reference, not a human protocol.
- Compound
- PT-141 (bremelanotide) — cyclic melanocortin-receptor agonist heptapeptide.
- Elimination half-life
- ≈2.7 hours (reported range ~1.9-4.0 hours).
- Kinetic class
- Short / acute — single-window, not multi-day accumulation.
- Reference route
- ~2.7h figure anchored to subcutaneous; intranasal absorbs differently.
- Titan format
- Metered nasal spray, $69.99 — no reconstitution required.
- Pathway
- Melanocortin receptors — distinct from GHRH/GHRP or GLP-1 compounds.
Questions researchers ask
Before you order.
- What is the half-life of PT-141?
- PT-141 (bremelanotide) has a reported elimination half-life of approximately 2.7 hours, with a literature range of roughly 1.9 to 4.0 hours. That places it in the short, acute end of the kinetic spectrum — it is modelled as a single-window compound rather than one that accumulates across days like a multi-day-cadence peptide.
- Why is PT-141 considered an acute compound?
- Because its half-life is short and systemic exposure does not stack across days. Research protocols model PT-141 around a single window — the size and timing of one exposure — rather than a steady-state level built up by repeated daily administration. That is the opposite design from a long-half-life peptide.
- Does the nasal spray change PT-141's half-life?
- The half-life describes how fast the compound is eliminated once absorbed, and the commonly-cited ~2.7-hour figure is anchored to subcutaneous administration. The intranasal route has its own absorption profile — typically lower and faster-peaking exposure — so the route shapes how much and how quickly the compound is absorbed, while elimination kinetics remain the reference figure.
- How does PT-141's half-life compare to Melanotan II?
- Both act on the melanocortin system, but they are distinct molecules with distinct kinetics and are studied for different endpoints. PT-141 (a metabolite-derived heptapeptide) is read on the short, acute clock described here. See the PT-141 vs Melanotan II page for the mechanistic and sourcing comparison — Titan stocks PT-141, not Melanotan II.
- Is PT-141 approved for human use?
- Titan Peptide Lab supplies PT-141 strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The kinetic figures on this page are a laboratory reference, not medical or dosing advice.